PubMed · 2209858
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
M V Ignat'ev. 1990. [Laxative agents].. https://pubmed.ncbi.nlm.nih.gov/2209858/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Explore the source record for details and available documents.
In this work, the swelling index is determined for various vegetable fibers (wheat bran. orange fibre and lemon fibre), and several granulated formulations to which different binding agents are added. The formulation that presents the highest swelling index (14.5 ml/g) was found to be composed of orange fibre, lemon fibre and pectin in a 1:1:1 proportion (OF + LF + PH). A study of the evolution of the swelling with time is also carried out, finding that the greatest volume increase is produced between 5 and 10 min from the start of the test. The application of the sigma-minus type calculation to the swelling rate curves produces correlation coefficients higher than 0.9. It is found that the swelling rate constant for lemon fibre is much lower than that of orange fibre. The addition of pectin lowers the swelling rate constant while the gum guar and polyvinylpyrrolidone increase the said constant. In addition, a general exponential equation is deduced which can be applied to all of the cases studied.
To put these predictions into perspective, the primary indication for lactulose therapy in the treatment of HE and SHE is presented and discussed. Six secondary indications for lactulose therapy are also listed and briefly commented upon. A dozen predictions about the status of lactulose are presented and briefly discussed. A. Lactulose will be the treatment of choice for HE.B. TIPS will be the most common cause of HE.C. Lactulose will not be approved in Mexico. D. Lactulose plus anti-diarrheal drugs will be agents for treatment of HE. E. Lactulose will not be the treatment of choice for constipation. F. Lactulose will not be used for Salmonella or Shigella carrier states. G. Lactulose will be routinely administered prophylactically after TIPS. H. Lactulose will be administered prophylactically to cirrhotic patients with portal hypertension. I. Lactulose plus anti-diarrheal drugs will be used for a variety of diverse purposes: (i) Suppression of bacterial growth; (ii) prevention of bacteriuria; (iii) diminution of cholesterol saturation of bile; (iv) adjunct treatment of gallstones with ursodeoxycholic acid; (v) Prevention of colon carcinoma.